| 303.345 -13.205 (-4.17%) | 05-14 12:02 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 366.22 |
1-year : | 383.55 |
| Resists | First : | 313.54 |
Second : | 328.39 |
| Pivot price | 304.02  |
|||
| Supports | First : | 289.53 |
Second : | 240.89 |
| MAs | MA(5) : | 311.51 |
MA(20) : | 306.34 |
| MA(100) : | 317.73 |
MA(250) : | 308.84 |
|
| MACD | MACD : | 1.5 |
Signal : | 0.7 |
| %K %D | K(14,3) : | 69.9 |
D(3) : | 76.3 |
| RSI | RSI(14): 47.3 |
|||
| 52-week | High : | 385.22 | Low : | 227.05 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ ONC ] has closed above bottom band by 47.4%. Bollinger Bands are 19.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 322.75 - 323.99 | 323.99 - 325.42 |
| Low: | 305.19 - 306.5 | 306.5 - 308 |
| Close: | 314.08 - 316.21 | 316.21 - 318.66 |
BeOne Medicines, formerly known as BeiGene, is a global oncology company focused on discovering, developing, and commercializing innovative cancer therapies. Founded in 2010 and headquartered in Cambridge, Massachusetts—with operations spanning over 45 countries across six continents—the company rebranded as BeOne in late 2024 and redomiciled to Basel, Switzerland in 2025. BeOne has established itself as a leader in immuno-oncology and targeted therapies, with key assets including Tevimbra (tislelizumab), a PD-1 monoclonal antibody approved for multiple cancer indications globally, and Brukinsa (zanubrutinib), a Bruton's tyrosine kinase (BTK) inhibitor that surpassed $1.3 billion in annual sales and is approved in major markets such as the U.S., Europe, and China. The company’s strategy combines internal R&D with the development of assets sourced from external partnerships, driving a robust pipeline across hematologic malignancies and solid tumors.
Wed, 13 May 2026
BEONE MEDICINES' BEQALZI Receives US Approval for Treatment of Adult Lymphoma Patients - AASTOCKS.com
Wed, 13 May 2026
BeOne Medicines (ONC) Receives FDA Fast-Tracked Approval for Beq - GuruFocus
Wed, 13 May 2026
ONC (NASDAQ: ONC) reports sale of 1,328 ADS via option exercise - Stock Titan
Wed, 13 May 2026
(sonrotoclax) Approved by U.S. FDA as First and Only BCL2 Inhibitor for R/R Mantle Cell Lymphoma - Business Wire
Mon, 11 May 2026
BeOne Medicines Ltd. (ONC) Stock Analysis: A 31.77% Upside Potential Powers Investor Optimism - DirectorsTalk Interviews
Sun, 10 May 2026
Citi Raises BeOne Medicines Ltd. (ONC.US) TP to USD453; 1Q26 Results Strong - AASTOCKS.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Pharmaceuticals
|
|
| Shares Out | 102 (M) |
| Shares Float | 1,010 (M) |
| Held by Insiders | 17.2 (%) |
| Held by Institutions | 32.1 (%) |
| Shares Short | 1,150 (K) |
| Shares Short P.Month | 1,510 (K) |
| EPS | 2.47 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 39.34 |
| Profit Margin | 5.3 % |
| Operating Margin | 12.3 % |
| Return on Assets (ttm) | 3.9 % |
| Return on Equity (ttm) | 7.4 % |
| Qtrly Rev. Growth | 32.7 % |
| Gross Profit (p.s.) | 45.65 |
| Sales Per Share | 52.2 |
| EBITDA (p.s.) | 5.65 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 1,130 (M) |
| Levered Free Cash Flow | 727 (M) |
| PE Ratio | 122.71 |
| PEG Ratio | 0 |
| Price to Book value | 7.7 |
| Price to Sales | 5.8 |
| Price to Cash Flow | 27.43 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|